News

AstraZeneca wins price recall for Forxiga generic drug in Russia

• By Newsdesk
• Russia
• Jun 20, 2023

News

Sandoz has retracted the price of Diapaglyph, a generic version of AstraZeneca's patented drug Forxiga (dapagliflozin). The AstraZeneca patent for Forxiga remains valid until 2028. This information was conveyed by the company's press service.

The act of registering a price for a drug before the expiration of its patent is regarded as a risky practice that has previously caused disruption in the pharmaceutical market. This situation serves as a reminder to all participants in the pharmaceutical industry that safeguarding and recognizing the intellectual property of pharmaceutical manufacturers is crucial for fostering healthy competition, encouraging innovation, and, most importantly, ensuring uninterrupted access to life-saving medications for patients.

On June 13, 2023, the Federal Antimonopoly Service approved the selling price for the generic Diapaglyph, manufactured by Sandoz. However, AstraZeneca promptly responded by demanding recognition of its patent protection, as it is the only legal producer and supplier of the drug with the international non-proprietary name (INN) dapagliflozin in the Russian Federation. In response to AstraZeneca's demand, Sandoz swiftly withdrew the price. AstraZeneca emphasizes that it will continue to take action against any attempts to infringe on its patents.

The manufacturing facility for the original drug Forxiga is situated in the Kaluga region. This medication is provided to patients with type 2 diabetes, chronic heart failure, and chronic kidney disease. The manufacturer assures that there is no risk of defects in this drug.